Life Science, Pharma & Chemicals:
Case Study

C▪H▪Reynolds was mandated by the investors in IEP – Future Capital AG (a technology fund of the state of Hessia and Sanofi-Aventis Group), HeidelbergCapital and Strategic European Technologies N.V. (SET– an investment fund under the management of Duke Forest) – to identify and approach potential buyers.

The main goal in this sellside transaction – besides optimization of the purchase price for the sellers – was the search for a strategic partner enabling IEP to expand further its R&D and distribution channels to focus on complementary applications in addition to existing ones.

IEP had already achieved an outstanding market position by combining biochemical, molecular biology and chemistry expertise with a portfolio of more than 100 enzymes and providing innovative, proprietary know-how. By expanding the new biocatalytic, enzyme-based green processes, IEP today optimizes the complex and expensive production processes of pharmaceutical, low-molecular APIs.

Cambrex is a leading producer of pharmaceutical APIs and related services for the Life Science indystry with R&D- and production facilities in the USA and Europe. Focus is the acceleration of development and commercialisation processes of low-molecular APIs, advanced pharmaceutics and other pharmaceutical products. Cambrex is a NYSE listed company.

One of the challenges with this sellside project was to protect IEPs proprietary know-how during parallel negotiations with several interested parties in a very narrow market.